Welcome to our dedicated page for TELESIS BIO news (Ticker: TBIO), a resource for investors and traders seeking the latest updates and insights on TELESIS BIO stock.
Telesis Bio, Inc. (NASDAQ: TBIO) is a leading synthetic biology company revolutionizing the field with its advanced technology for building high-quality synthetic DNA and mRNA. Based in San Diego, Telesis Bio manufactures and distributes a variety of laboratory equipment including synthetic biology instruments, reagents, and related services that empower researchers in various scientific domains.
The company's flagship product, the BioXp® system, is an award-winning, fully automated genomics workstation that streamlines the entire synthesis, cloning, and amplification workflow. This system consolidates various processes, enabling the creation of double-stranded DNA fragments, automated cloning, and next-generation sequencing DNA library preparation. The BioXp system is complemented by BioXp kits, Benchtop reagents, and BioXp biofoundry services, all designed to accelerate synthetic biology workflows.
Telesis Bio is known for its industry-standard Gibson Assembly® method, an essential tool for assembling DNA molecules. The company recently launched the groundbreaking Gibson SOLA platform, which supports high-throughput drug discovery applications and promises significant advantages over existing solutions. This platform ensures high-fidelity synthesis of synthetic oligonucleotides, genes, and transfection-ready mRNA, allowing researchers to achieve results within unprecedented timelines.
In its recent updates, Telesis Bio announced several milestones, including the introduction of new kits to expand their suite of NGS Library Prep solutions on the BioXp System. The company has shown resilience and adaptability, with revenue for the third quarter of 2023 at $5.6 million, despite a challenging economic environment. Their ongoing efforts in cost-cutting have effectively reduced operating expenses and net losses, laying a strong foundation for future growth.
Telesis Bio's technology is crucial in multiple fields, including precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Researchers worldwide rely on their solutions to accelerate the design-build-test paradigm, pushing the boundaries of synthetic biology to address some of humanity's greatest challenges.
As Telesis Bio continues to innovate and expand, they remain committed to providing researchers with the tools and resources needed to drive scientific discovery and application. For more information, visit www.telesisbio.com.
Translate Bio (Nasdaq: TBIO) announced the appointment of Dr. Rand Sutherland as President, effective March 22, 2021. With 20 years of experience in the medical and industry sectors focusing on pulmonary and rare diseases, Dr. Sutherland previously led Global Medical Affairs at Sanofi Genzyme. In his new role, he will oversee research, development, and corporate strategy to enhance the company’s mRNA therapeutic pipeline. CEO Ronald Renaud emphasized Dr. Sutherland's critical role in advancing the company’s innovative mRNA medicines, targeting genetic diseases, and improving patient care.
Translate Bio has reported promising interim results from its Phase 1/2 clinical trial of MRT5005, designed to treat cystic fibrosis (CF) by delivering mRNA encoding CFTR protein to the lungs. The trial showed that multiple doses of MRT5005 were generally safe and well tolerated with no serious adverse events. However, there was no observed pattern of increase in lung function, measured by percent predicted forced expiratory volume in 1 second (ppFEV1). The company plans further research to optimize the therapeutic approach and advance its next-generation CF candidate.
Translate Bio and Sanofi Pasteur have initiated a Phase 1/2 clinical trial for MRT5500, an mRNA vaccine candidate targeting SARS-CoV-2. The trial aims to enroll 415 participants and evaluate safety, immune response, and tolerability. Interim results are expected in Q3 2021. Upon trial initiation, Translate Bio will receive a $25 million payment. Preclinical data indicated high neutralizing antibody levels, with ongoing studies assessing responses to emerging variants. The collaboration reflects significant progress in mRNA vaccine development for infectious diseases.
On March 1, 2021, Translate Bio (Nasdaq: TBIO) announced the grant of non-qualified stock options for 54,250 shares to seven new employees. This move, part of the 2021 Inducement Stock Incentive Plan, is intended to incentivize staff acceptance of employment. The options carry an exercise price of $23.80 per share, matching the closing stock price on the same day, with a vesting schedule over four years. Translate Bio focuses on mRNA therapeutics, particularly in treating pulmonary diseases and developing mRNA vaccines through a collaboration with Sanofi Pasteur.
Translate Bio (Nasdaq: TBIO) reported its fourth quarter and full year 2020 results, showcasing significant developments in its mRNA therapeutics pipeline. The company expects interim data from the Phase 1/2 trial of MRT5005 for cystic fibrosis in early Q2 2021 and plans to initiate two infectious disease vaccine programs, including COVID-19 and influenza, in collaboration with Sanofi Pasteur. Despite a net loss of $20.6 million in Q4 2020, collaboration revenue rose to $51.4 million, driven by increased vaccine activities. With $654 million in cash, the firm believes it can sustain operations through 2023.
Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, announced CEO Ronald Renaud's participation in a fireside chat at the SVB Leerink Virtual 10th Annual Global Healthcare Conference on February 26, 2021, at 9:20 a.m. EST. This event highlights the company's focus on transformative mRNA medicines aimed at treating life-threatening diseases, particularly pulmonary diseases like cystic fibrosis. Interested parties can access the live webcast via the company's website, with archived replays available for 30 days.
Translate Bio (Nasdaq: TBIO) announced on February 1, 2021, the grant of non-qualified stock options to purchase 57,550 shares to four new employees. These options, part of the 2021 Inducement Stock Incentive Plan, have an exercise price of $24.46 per share and a ten-year term, vesting over four years. The Company's lead candidate aims to treat cystic fibrosis and is currently in a Phase 1/2 clinical trial. Translate Bio is also developing mRNA vaccines for infectious diseases in collaboration with Sanofi Pasteur.
Translate Bio (NASDAQ: TBIO) has completed enrollment and dosing for its Phase 1/2 clinical trial of MRT5005, the first mRNA therapeutic administered via nebulization for cystic fibrosis. This trial includes 8, 12, and 16 mg multiple-ascending dose groups, alongside a 20 mg single-ascending dose group. Interim clinical data is expected early in Q2 2021. MRT5005 aims to treat all CF patients regardless of genetic mutation, addressing a significant unmet need. The FDA has granted MRT5005 several designations, including Orphan Drug and Fast Track.
Translate Bio (Nasdaq: TBIO) announced the departure of Chief Financial Officer John Schroer, effective year-end 2020, due to personal reasons. Robert Prentiss, Vice President and Corporate Controller, will serve as Principal Accounting Officer during the interim period until a new CFO is appointed. CEO Ronald Renaud acknowledged Schroer's contributions in transitioning to a public company and advancing strategic partnerships, especially in infectious disease vaccines. Translate Bio is focused on developing mRNA therapeutics for treating pulmonary diseases and has a lead candidate in a Phase 1/2 clinical trial for cystic fibrosis.
Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, announced its participation in two upcoming investor conferences. John Schroer, CFO, will present a corporate overview at the Jefferies Virtual London Healthcare Conference on November 18, 2020, at 7:55 a.m. ET. CEO Ronald Renaud will engage in a fireside chat at the Evercore ISI HealthCONx Conference on December 2, 2020, at 2:15 p.m. ET. Live webcasts of these presentations will be available on the company's website, with replays archived for 30 days.
FAQ
What is the current stock price of TELESIS BIO (TBIO)?
What is the market cap of TELESIS BIO (TBIO)?
What is Telesis Bio, Inc. known for?
What are the main products offered by Telesis Bio?
How does the BioXp® system benefit researchers?
What recent achievements has Telesis Bio announced?
What is the Gibson SOLA platform?
Where is Telesis Bio located?
How has Telesis Bio performed financially recently?
What industries benefit from Telesis Bio's technology?
How can I learn more about Telesis Bio's offerings?
What are Telesis Bio's future plans?
